APO RESEARCH · REPORT
Liposomal Doxorubicin
Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
Product & engineering
Understand the product.
Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
Selected research
Industry Research
Liposomal Doxorubicin Industry Research Report 2026
Market perspective
Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.
Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.
Report Scope
Read the full market overview
This report quantifies the global Liposomal Doxorubicin market in terms of revenue (US$ million) and, where applicable, sales volume (K Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomal Doxorubicin Market by Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Liposomal Doxorubicin Segment by Type
5 ml
10 ml
25 ml
Liposomal Doxorubicin Segment by Application
Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
Liposomal Doxorubicin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal Doxorubicin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal Doxorubicin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal Doxorubicin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liposomal Doxorubicin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liposomal Doxorubicin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5 ml
- 10 ml
- 25 ml
Applications
- Breast Cancer
- Liver Cancer
- Kidney Cancer
- Multiple Myeloma
- Ovarian Cancer
- Other
Companies covered
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Kinyond
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liposomal Doxorubicin Market Size (2021-2032)
- 2.2.2 Global Liposomal Doxorubicin Sales (2021-2032)
- 2.2.3 Global Liposomal Doxorubicin Market Average Price (2021-2032)
- 2.3 Liposomal Doxorubicin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5 ml
- 2.3.3 10 ml
- 2.3.4 25 ml
- 2.4 Liposomal Doxorubicin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Liver Cancer
- 2.4.4 Kidney Cancer
- 2.4.5 Multiple Myeloma
- 2.4.6 Ovarian Cancer
- 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liposomal Doxorubicin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liposomal Doxorubicin Sales (K Unit) of Manufacturers (2021-2026)
- 3.3 Global Liposomal Doxorubicin Revenue of Manufacturers (2021-2026)
- 3.4 Global Liposomal Doxorubicin Average Price by Manufacturers (2021-2026)
- 3.5 Global Liposomal Doxorubicin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liposomal Doxorubicin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liposomal Doxorubicin, Product Type & Application
- 3.8 Global Manufacturers of Liposomal Doxorubicin, Established Date
- 3.9 Global Liposomal Doxorubicin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Liposomal Doxorubicin Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 CSPC
- 4.3.1 CSPC Company Information
- 4.3.2 CSPC Business Overview
- 4.3.3 CSPC Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CSPC Liposomal Doxorubicin Product Portfolio
- 4.3.5 CSPC Recent Developments
- 4.4 Kinyond
- 4.4.1 Kinyond Company Information
- 4.4.2 Kinyond Business Overview
- 4.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kinyond Liposomal Doxorubicin Product Portfolio
- 4.4.5 Kinyond Recent Developments
- 4.5 Teva
- 4.5.1 Teva Company Information
- 4.5.2 Teva Business Overview
- 4.5.3 Teva Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Teva Liposomal Doxorubicin Product Portfolio
- 4.5.5 Teva Recent Developments
- 4.6 Fudan-Zhangjiang
- 4.6.1 Fudan-Zhangjiang Company Information
- 4.6.2 Fudan-Zhangjiang Business Overview
- 4.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Portfolio
- 4.6.5 Fudan-Zhangjiang Recent Developments
- 4.7 Zydus Cadila
- 4.7.1 Zydus Cadila Company Information
- 4.7.2 Zydus Cadila Business Overview
- 4.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Cadila Liposomal Doxorubicin Product Portfolio
- 4.7.5 Zydus Cadila Recent Developments
- 4.8 TTY Biopharma
- 4.8.1 TTY Biopharma Company Information
- 4.8.2 TTY Biopharma Business Overview
- 4.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 TTY Biopharma Liposomal Doxorubicin Product Portfolio
- 4.8.5 TTY Biopharma Recent Developments
5 Global Liposomal Doxorubicin Market Scenario by Region
- 5.1 Global Liposomal Doxorubicin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liposomal Doxorubicin Sales by Region: 2021-2032
- 5.2.1 Global Liposomal Doxorubicin Sales by Region: 2021-2026
- 5.2.2 Global Liposomal Doxorubicin Sales by Region: 2027-2032
- 5.3 Global Liposomal Doxorubicin Revenue by Region: 2021-2032
- 5.3.1 Global Liposomal Doxorubicin Revenue by Region: 2021-2026
- 5.3.2 Global Liposomal Doxorubicin Revenue by Region: 2027-2032
- 5.4 North America Liposomal Doxorubicin Market Facts & Figures by Country
- 5.4.1 North America Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.4.3 North America Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Liposomal Doxorubicin Market Facts & Figures by Country
- 5.5.1 Europe Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.5.3 Europe Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Liposomal Doxorubicin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liposomal Doxorubicin Market Facts & Figures by Country
- 5.7.1 South America Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.7.3 South America Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Liposomal Doxorubicin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liposomal Doxorubicin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liposomal Doxorubicin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liposomal Doxorubicin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Liposomal Doxorubicin Sales by Type (2021-2032)
- 6.1.1 Global Liposomal Doxorubicin Sales by Type (2021-2032) & (K Unit)
- 6.1.2 Global Liposomal Doxorubicin Sales Market Share by Type (2021-2032)
- 6.2 Global Liposomal Doxorubicin Revenue by Type (2021-2032)
- 6.2.1 Global Liposomal Doxorubicin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liposomal Doxorubicin Revenue Market Share by Type (2021-2032)
- 6.3 Global Liposomal Doxorubicin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liposomal Doxorubicin Sales by Application (2021-2032)
- 7.1.1 Global Liposomal Doxorubicin Sales by Application (2021-2032) & (K Unit)
- 7.1.2 Global Liposomal Doxorubicin Sales Market Share by Application (2021-2032)
- 7.2 Global Liposomal Doxorubicin Revenue by Application (2021-2032)
- 7.2.1 Global Liposomal Doxorubicin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liposomal Doxorubicin Revenue Market Share by Application (2021-2032)
- 7.3 Global Liposomal Doxorubicin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liposomal Doxorubicin Value Chain Analysis
- 8.1.1 Liposomal Doxorubicin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liposomal Doxorubicin Production Mode & Process
- 8.2 Liposomal Doxorubicin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liposomal Doxorubicin Distributors
- 8.2.3 Liposomal Doxorubicin Customers
9 Global Liposomal Doxorubicin Analyzing Market Dynamics
- 9.1 Liposomal Doxorubicin Industry Trends
- 9.2 Liposomal Doxorubicin Industry Drivers
- 9.3 Liposomal Doxorubicin Industry Opportunities and Challenges
- 9.4 Liposomal Doxorubicin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst